A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
Conditions
Duchenne Muscular Dystrophy (DMD)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University Hospital Gent, Ghent, Belgium
Contact: Principal Investigator (Nicolas Deconinck)UZ Leuven, Leuven, Belgium
Contact: Principal Investigator (Liesbeth De Waele)Centre Hospitalier Régional de la Citadelle, Liège, Belgium
Contact: Principal Investigator (Aurore Daron)IRCCS Ospedale San Raffaele, Milan, Italy
Contact: Principal Investigator (Stefano Previtali)Fondazione Serena Onlus - Centro Clinico NeMO Milano, Milan, Italy
Contact: Study coordinator (Valeria Sansone) · valeria.sansone@centrocliniconemo.it · +39 3495607450Contact: Principal Investigator (Valeria Sansone)Ospedale Pediatrico Bambino Gesu, Rome, Italy
Contact: Principal Investigator (Adele D'Amico)Hospital Universitario Vall d'Hebron, Barcelona, Spain
Contact: Principal Investigator (David Gomez Andres)Hospital Sant Joan de Deu, Barcelona, Spain
Contact: Principal Investigator (Andres Nascimento)Leeds General Infirmary, Leeds, United Kingdom
Contact: Principal Investigator (Cristina Martos Lozano)Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
Contact: Principal Investigator (Rajesh Madhu)Great Ormond Street Hospital for Children, London, United Kingdom
Contact: Principal Investigator (Mariacristina Scoto)Royal Manchester Children's Hospital, Manchester, United Kingdom
Contact: Principal Investigator (Gary McCullagh)Freeman Hospital, Newcastle upon Tyne, United Kingdom
Contact: Principal Investigator (Michela Guglieri)Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Contact: Principal Investigator (Laurent Servais)
Study leads
Entrada Therapeutics Clinical Trials
Study Director
Entrada Therapeutics, Inc.